PM · Philip Morris International
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $214.35
Note written ·
Price against the kill line
9.3% clear of its kill line on the 17 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $214.35, set on 15 November 2026. The shares are up 3.2% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $214.35, above the 30 October 2026 52-week high, which would show the shares leading; or fourth-quarter 2026 U.S. operating income clearly above the "around zero" management guided on 21 October 2026.
Research onlyNot in the portfolio.
Catalyst
The business · as of
Philip Morris International sells Marlboro cigarettes and smoke-free nicotine products, mainly IQOS heated tobacco and ZYN nicotine pouches, to wholesalers and retailers worldwide. It earns money mostly through price increases on steady volumes. Revenue was $11,438 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 21 October 2026 the company reported third-quarter revenue up 5.5% to $11,438 million. It is moving most U.S. ZYN cans from 15 to 20 pouches at the same price, about 25% less revenue per pouch.
- What follows for the company
- Management expects U.S. operating income to fall from $171 million in the third quarter to around zero in the fourth as U.S. spending rises. It guides organic operating income growth to the middle or lower half of 7–9%.
- What follows for its customers, suppliers and competitors
- More ZYN pouches for the same price adds pressure on Altria (MO), whose on! brand held 13.4% of U.S. pouch sales in the first quarter according to TIKR, and on British American Tobacco (BTI).
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 23 October 2026) the shares trade at 29.0 times earnings, 21.1 times EV/EBIT and 8.1 times sales, with a 4.4% free-cash-flow yield. That holds only if revenue keeps growing near the 5.5% of the latest filed quarter and the operating margin stays near that quarter's 42.5% through the U.S. ZYN price reset.
Key figures from the filings · Consumer Staples
Quarter to 30 September 2026, filed 23 October 2026; valuation at the 17 November 2026 close
- Revenue, latest quarter ($M)
- 11,438
- Revenue, change on a year (%)
- +5.5
- Gross margin (%)
- 68.7
- Operating margin (%)
- 42.5
- Free cash flow, four quarters ($M)
- 13,595
- Net cash, cash less debt ($M)
- −40,879
- Price to earnings (×)
- 28.3
- Enterprise value to sales (×)
- 8.0
All filed numbers
What Philip Morris International reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 11,438 | +5.5 | 68.7 | 42.5 |
| first filed | 11,192 | +10.4 | 68.4 | 40.5 |
| first filed | 10,146 | +9.1 | 68.1 | 38.4 |
| first filed | 10,362 | +6.8 | 65.6 | 32.6 |
| first filed restated | 10,845 | +9.4 | 67.9 | 39.3 |
| first filed restated | 10,140 | +7.1 | 67.7 | 36.6 |
| Pre-tax income ($M) | 4,594 |
| Net income ($M) four quarters: 10,709 | 3,313 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +0.1 |
| Operating cash flow ($M) | 15,154 |
| Capital spending ($M) | 1,559 |
| Free cash flow ($M) | 13,595 |
| Cash and short-term investments ($M) | 6,683 |
| Debt ($M) long-term debt and finance leases plus short-term borrowings | 47,562 |
| Net cash, cash less debt ($M) | −40,879 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 5,156 |
| Inventory ($M) | 10,326 |
| Shareholders' equity ($M) | −7,937 |
| Market value ($M) | 302,972 |
| Enterprise value, market value plus net debt ($M) | 343,851 |
| Enterprise value to sales (×) | 8.0 |
| Enterprise value to operating income (×) | 20.6 |
| Price to earnings (×) | 28.3 |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | 4.5 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 0.9% of shares outstanding sold short, 3.2 days of average trading to cover, −14.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Competitors:
- MO, BTI
The thesis
Philip Morris International is more likely to lag the S&P 500 over the next three months. The shares trade at 29.0 times earnings while management has guided U.S. ZYN profit to around zero in the fourth quarter of 2026. The fourth-quarter report and the 2027 outlook, expected in early February 2027, settle it.
The rating is Low because the business is growing but the next report carries a guided profit dip. On 21 October 2026 the company reported third-quarter revenue of $11,438 million, up 5.5% from a year earlier and 7.1% organically, and adjusted diluted earnings per share (EPS) of $2.36, up 5.4%. In the same release it kept its ex-currency 2026 adjusted EPS forecast at $8.11–8.26 and cut the expected currency benefit to $0.18 from $0.24. It also guided organic operating income growth to the middle or lower half of its 7–9% range.
The main problem is the U.S. pouch business. Most flagship ZYN cans are moving from 15 to 20 pouches at the same price. On the 22 October 2026 call, finance chief Massimo Andolina said this means about 25% less revenue per pouch, according to TIKR. Management expects U.S. operating income, $171 million in the third quarter, to be "around zero or slightly negative" in the fourth.
Bullish and bearish views on Philip Morris International Inc.
The bull case on Philip Morris International Inc. (PM), in brief: pricing still drives record profits. The bear case: U.S. profit has fallen sharply.
Bull case
- Pricing still drives record profits. The 21 October 2026 release showed $739 million of favourable pricing in the third quarter and record quarterly revenue, gross profit and operating income. The operating margin was 42.5% in the quarter to 30 September 2026, against 39.3% a year earlier (10-Q filed 23 October 2026).
- Cigarette volumes are holding up better than planned. Cigarette volume was flat in the third quarter and down 1.2% over the first nine months of 2026. On 21 October 2026 the company dropped its earlier assumption of a 2–3% full-year decline.
- Cash funds a rising dividend. Free cash flow was $13,595 million over the four quarters to 30 September 2026 (10-Q). On 21 October 2026 the board raised the quarterly dividend 8.8% to $1.60.
- Smoke-free sales are now a large share of revenue. Smoke-free products made up more than 40% of third-quarter net revenue and about 42% of the year to date (21 October 2026 release). IQOS heated-tobacco shipments rose 1.5% to 41.5 billion units.
- Some analysts see room above the price. Stifel kept a Buy rating and raised its target to $232 from $205 on 3 November 2026. Argus raised its target to $220 on 26 October 2026.
Bear case
- U.S. profit has fallen sharply. U.S. adjusted operating income fell 41.1% organically to $550 million over the first nine months of 2026 (21 October 2026 release). Management expects U.S. selling and administrative costs, about $370 million in the third quarter, to rise another 10% in the fourth, according to TIKR's 22 October 2026 summary of the call.
- ZYN growth has slowed. U.S. ZYN shipments rose only 4.2% to 3.2 billion pouches in the third quarter (21 October 2026 release). A Jefferies analyst cited scanner data showing a mid-single-digit fall in U.S. ZYN volumes over the same quarter, as reported by TIKR on 22 October 2026.
- The valuation already assumes growth. At the 13 November 2026 close the shares trade at 29.0 times reported earnings and 21.1 times operating profit including debt. TIKR put the forward multiple at 21.97 times on 22 October 2026, against a five-year average of 17.85 times.
- Balance sheet leaves no room for buybacks. Debt was $47,562 million and shareholders' equity was negative $7,937 million at 30 September 2026 (10-Q). The company said on 21 October 2026 that it plans no share repurchases in 2026.
- The newest analyst rating sits at the price. JPMorgan reinstated coverage at Neutral with a $200 target on 10 November 2026.
- Regulation keeps tightening. On 29 October 2026 the UK health department extended its under-18 sales ban to nicotine products and all vapes. On 12 November 2026 Politico reported that European cities are asking for an EU-wide ban on cigarette filters.
Price setup
The shares closed at $198.96 on 13 November 2026. That is 7.2% below the 52-week intraday high of $214.35 set on 30 October 2026, and 8.8% above the adjusted close three months earlier. The 50-day moving average is $195.68 and the 200-day moving average is $180.97, both from adjusted daily closes as of 13 November 2026. The 52-week closing low was $147.81 on 5 December 2025.
On report day, 21 October 2026, the shares closed at $197.46, down 1.22%, after trading near $194 (TIKR). They then rose to the 30 October 2026 high and fell back to close at $193.12 on 9 November 2026, below the 50-day average. They recovered to $198.96 by 13 November 2026. The price now sits just above the 50-day average and near JPMorgan's $200 target. A move back above the October high would mean investors are looking past the fourth-quarter profit dip.
Catalysts ahead
- ~29 January 2027 (est.): Altria fourth-quarter 2026 report. Altria's on! pouch results show whether the cheaper ZYN cans are winning share from the main U.S. competitor.
- ~5 February 2027 (est.): Philip Morris International fourth-quarter 2026 results and 2027 outlook. This report shows whether U.S. operating income fell to around zero as guided, and whether 2027 EPS guidance supports a multiple of 29.0 times earnings.
- ~16 February 2027 (est.): CAGNY consumer conference presentation. Management usually restates or updates the year's forecast at this conference, which shows whether the 2027 outlook holds.
What would change the view
A daily close above $214.35, above the 30 October 2026 52-week high, which would show the shares leading; or fourth-quarter 2026 U.S. operating income clearly above the "around zero" management guided on 21 October 2026.
What it trades with
A common market view is that tobacco shares trade as defensive holdings that lag when growth stocks rally. On 9 November 2026 the Nasdaq 100 rose 3% as chip stocks rebounded, and Philip Morris fell from $197.88 to $193.12. The shares are most closely linked to news from Altria (MO), which competes with ZYN through on!, and from British American Tobacco (BTI). Most revenue is earned outside the United States, so the dollar affects reported EPS. The 21 October 2026 cut to the currency benefit, to $0.18 from $0.24, shows how currency moves feed into the forecast.
Caveats
- Shareholders' equity is negative, at −$7,937 million at 30 September 2026, against debt of $47,562 million, so price-to-book is not a meaningful measure for this company. Form 10-Q for the third quarter of 2026 · as of
The evidence, claim by claim (8)
- Third-quarter 2026 net revenue was $11.4 billion, up 5.5% reported and 7.1% organically; adjusted diluted EPS was $2.36, up 5.4%, and reported diluted EPS was $2.12, down 4.9%. PMI third-quarter 2026 results release · as of
- The 2026 adjusted diluted EPS forecast is $8.29–8.44; the ex-currency range of $8.11–8.26 is unchanged, and the currency benefit was cut to $0.18 from $0.24. PMI third-quarter 2026 results release · as of
- U.S. ZYN shipments rose 4.2% to 3.2 billion pouches in the third quarter, and IQOS heated-tobacco unit shipments rose 1.5% to 41.5 billion. PMI third-quarter 2026 results release · as of
- U.S. adjusted operating income was $171 million in the third quarter, and fell 41.1% organically to $550 million over the first nine months of 2026. PMI third-quarter 2026 results release · as of
- Management guided U.S. operating income to around zero or slightly negative in the fourth quarter of 2026, as ZYN moves to 20-pouch cans at about 25% less revenue per pouch. 21 October 2026 earnings call, as reported by TIKR · as of
- The quarterly dividend was raised 8.8% to $1.60, and the company plans no share repurchases in 2026. PMI third-quarter 2026 results release · as of
- Operating margin was 42.5% in the quarter to 30 September 2026, against 39.3% a year earlier; free cash flow was $13,595 million over the four quarters to that date. Form 10-Q for the third quarter of 2026 · as of
- JPMorgan reinstated coverage at Neutral with a $200 price target on 10 November 2026, after Stifel kept a Buy rating and raised its target to $232 from $205 on 3 November 2026. Benzinga analyst ratings reports · as of
Sources